Effects of Amiloride on Chronic Kidney Disease Progression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, placebo-controlled, double-blinded crossover trial investigates the impact of amiloride on patients with chronic kidney disease (CKD) and proteinuria. The study aims to determine if amiloride can protect the kidney filtration barrier, reduce albuminuria, and decrease kidney inflammation without affecting blood pressure. Participants will receive either amiloride or a placebo for one week, followed by a washout period before switching treatments. Blood and urine samples will be collected to assess the drug's efficacy.

Why it matters

Who can join: the full rules

Inclusion criteria

Participants are eligible to be included in the study, only if all the following criteria apply:

1. Participant must be 18 years of age including at the time of signing the informed consent.
2. A clinical diagnosis of chronic kidney disease and:

   1. eGFR ≥ 25 mL/min/1.73m2 and \< 60mL/ min/1.73m2 at screening
   2. UACR of ≥ 300mg/g at screening
3. Participants must be on stable antihypertensive treatment 2 weeks before start of study drug and throughout study duration.
4. Office blood pressure at screening meeting (visit 1), \> 110/60mmHg and \< 150/90mmHg. If BP \> 150/90mmHg at visit 1, screening phase can be prolonged to 4 weeks#.
5. Capable of giving signed informed consent.
6. Women with childbearing potential\* can only be included if a pregnancy test is negative at the screening visit. Moreover, women should be using contraception during the study.

   * If the office blood pressure varies by approximately ±10 mmHg and is deemed acceptable by the investigator, the participant can be included.

     * Women are considered of childbearing potential following menarche and until becoming post-menopausal (12 consecutive months without a menstrual period) unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy or bilateral oophorectomy (According to the Clinical Trial Facilitation Group, 2014-09-15).

Exclusion criteria

Participants are excluded from the study is any of the following criteria apply:

1. Treatment with amiloride alone or in combination or use of other types of K-sparing diuretics, MR antagonists (Spironolactone, eplerenone, finerenone)
2. Ongoing cancer treatment
3. Treatment with immunosuppressive therapy within 6 months prior to screening
4. History of organ transplantation
5. Evidence of current infection (CRP\> 50 and temperature \> 38◦C)
6. History of unstable or rapidly progressing renal disease (eGFR decreasing \> 5ml/min/1.73m2 the last 2 months)
7. Severe hepatic insufficiency classified as Child-Pugh C
8. Patients on hypertension treatment who is not on stable antihypertensive treatment 2 weeks before start of study drug.
9. Pregnancy or breastfeeding participants
10. Congestive heart failure NYHA class IV, unstable or acute congestive heart failure.
11. Recent cardiovascular events in a patient:

    1. Less than two months post coronary artery revascularization.
    2. Acute stroke or TIA within two months prior to screening
    3. Acute coronary syndrome within two months prior to screening
12. Patients who, in the judgement of the investigator may be at risk for dehydration.
13. Known hypersensitivity to the study treatment (active substance or excipients)
14. Known hypersensitivity to resonium
15. Addison´s disease
16. Gastric bypass operation
17. Participation in other interventional trials
18. Lactose intolerance
19. Plasma potassium \>4.9 mmol/l at screening

Where it's running

• Department of Nephrology, Odense University Hospital
  Odense, Denmark Recruiting

Study contacts

• Study coordinator: Gitte Rye Hinrichs, MD, PhD
• Email: gitte.rye.hinrichs2@rsyd.dk
• Phone: 004521695186

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines

  This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.

  Recruiting at 2 sites St. James's Hospital, Ireland · Dublin and 1 other locations · NCT07561957

• Biomarker-guided treatment strategy for chronic kidney disease

  This trial will test whether using urine biomarkers to guide adding dapagliflozin, finerenone, and/or semaglutide can better reduce albuminuria and protect kidneys in adults with CKD.

  Recruiting Phase 4 Steno Diabetes Center Copenhagen · Herlev and 3 other locations · NCT07239570

• Sparsentan for high-grade proteinuria linked to VEGF inhibitors

  This pilot study tests whether sparsentan can reduce severe proteinuria in adults with cancer who are being treated with VEGF signaling pathway inhibitors.

  Recruiting Phase 1 Brigham and Women's Hospital · Boston, Massachusetts · NCT07224776

• Algae supplements for heart risk markers and gut health

  This trial will test whether daily supplements of spirulina or Gelidium corneum change gut microbes and improve heart‑disease risk markers in adults over 50 with cardiovascular disease, diabetes, or related conditions.

  Recruiting Universidade do Porto · Porto · NCT07173062

• Validating lab assays, IV catheter techniques, and devices for endocrine, cardiometabolic, and musculoskeletal conditions

  This project will test whether laboratory assays, IV catheter methods, and equipment give consistent, reliable results in adults with or without obesity-related, metabolic, or musculoskeletal conditions.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07083557

• Heart, kidney, and metabolic health in Shanghai community residents

  This follow-up will track people from the STONE cohort to see if changes in metabolic risk factors over time relate to heart and kidney outcomes.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07043166

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.